Share on StockTwits
 

Globus Medical (NASDAQ:GMED) COO David Demski unloaded 3,187 shares of Globus Medical stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $20.25, for a total value of $64,536.75. Following the sale, the chief operating officer now directly owns 478,178 shares in the company, valued at approximately $9,683,105. The transaction was disclosed in a filing with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Piper Jaffray raised their price target on shares of Globus Medical from $22.00 to $25.00 in a research note to investors on Thursday, October 31st. They now have an “overweight” rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of Globus Medical from $24.00 to $26.00 in a research note to investors on Thursday, October 31st. They now have a “buy” rating on the stock. Finally, analysts at Goldman Sachs Group Inc. downgraded shares of Globus Medical from a “buy” rating to a “neutral” rating in a research note to investors on Monday, October 14th. They now have a $18.00 price target on the stock, down previously from $19.00. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $21.40.

Globus Medical (NASDAQ:GMED) traded down 2.13% on Thursday, hitting $19.75. The stock had a trading volume of 1,295,665 shares. Globus Medical has a 1-year low of $10.55 and a 1-year high of $20.25. The stock’s 50-day moving average is $19.17 and its 200-day moving average is $17.80. The company has a market cap of $1.842 billion and a P/E ratio of 27.68.

Globus Medical (NASDAQ:GMED) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.03. The company had revenue of $107.19 million for the quarter, compared to the consensus estimate of $106.00 million. During the same quarter in the previous year, the company posted $0.18 earnings per share. The company’s revenue for the quarter was up 13.1% on a year-over-year basis.

Globus Medical, Inc (NASDAQ:GMED) is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.